Prognostic Ability of DNA-binding Protein Inhibitor ID-1 Expression in Patients with Oral Squamous Cell Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2020 May 9

PMID 32382338

Citations 3

Authors

Jian Chen

Fan Zhang

Dong Wang

Zhongjun Yang

Shaohua Liu

Zuoqing Dong

Affiliations

Soon will be listed here.

Abstract

DNA-binding protein inhibitor ID-1 (ID-1) plays a vital role in the development of cancer. In the present study, ID-1 expression in oral squamous cell carcinoma (OSCC), and its association with prognosis were investigated in 128 patients with OSCC, treated at the Qilu Hospital of Shandong University and followed up for an additional 10 years. Immunohistochemical analysis was performed to detect ID-1 expression, and the association between ID-1 expression and recurrence, and estimated disease-specific survival (DSS) time were subsequently analyzed using the Mann-Whitney U test and the Kaplan-Meier method, respectively. In addition, the log-rank test was implemented to compare the survival curves and multivariate Cox proportional hazards analysis was performed to assess the prognostic value of ID-1. The results demonstrated that ID-1 was highly expressed in the majority of OSCC tissues investigated, and ID-1 expression was significantly higher in cases with recurrence of local tumors and lymph node metastasis. Furthermore, higher ID-1 expression levels were associated with a shorter DSS time. Taken together, the results of the present study suggest that ID-1 may serve as an independent prognostic factor to predict DSS time in patients with OSCC.

Citing Articles

Advances in the functions of CTRP6 in the development and progression of the malignancy.

Hu B, Qian X, Qian P, Xu G, Jin X, Chen D Front Genet. 2022; 13:985077.

PMID: 36313428 PMC: 9596804. DOI: 10.3389/fgene.2022.985077.

Micellar Casein and Whey Powder Hold a TGF-β Activity and Regulate ID Genes In Vitro.

Panahipour L, Husejnovic S, Nasirzade J, Semelmayer S, Gruber R Molecules. 2021; 26(2).

PMID: 33477984 PMC: 7835755. DOI: 10.3390/molecules26020507.

Effects of BAP1, Ki-67 index, and Id-1 in patients with clear cell renal carcinoma and their correlation with clinical features and prognosis.

Yang J, Gong C, Zhao J, Chen L, Mei X, Li G Transl Androl Urol. 2020; 9(5):2242-2250.

PMID: 33209689 PMC: 7658141. DOI: 10.21037/tau-20-1258.

References

Perk J, Iavarone A, Benezra R . Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer. 2005; 5(8):603-14. DOI: 10.1038/nrc1673. View

Nishimine M, Nakamura M, Mishima K, Kishi M, Kirita T, Sugimura M . Id proteins are overexpressed in human oral squamous cell carcinomas. J Oral Pathol Med. 2003; 32(6):350-7. DOI: 10.1034/j.1600-0714.2003.00078.x. View

Chow L . Head and Neck Cancer. N Engl J Med. 2020; 382(1):60-72. DOI: 10.1056/NEJMra1715715. View

Li J, Li Y, Wang B, Ma Y, Chen P . Id-1 promotes migration and invasion of non-small cell lung cancer cells through activating NF-κB signaling pathway. J Biomed Sci. 2017; 24(1):95. PMC: 5727929. DOI: 10.1186/s12929-017-0400-6. View

Zhao J, Wang S, Liu N, Tang X . Correlation between the expression of Id-1 and hyperthermia-associated molecules in oral squamous cell carcinoma. J Clin Pathol. 2013; 66(9):758-63. DOI: 10.1136/jclinpath-2011-200287. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Sun W, Guo M, Han P, Lin J, Liang F, Tan G . Id-1 and the p65 subunit of NF-κB promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis. 2012; 33(4):810-7. DOI: 10.1093/carcin/bgs027. View

Dong Z, Wei F, Zhou C, Sumida T, Hamakawa H, Hu Y . Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol. 2010; 47(1):27-32. DOI: 10.1016/j.oraloncology.2010.10.012. View

Patel S, Amit M, Yen T, Liao C, Chaturvedi P, Agarwal J . Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research. Br J Cancer. 2013; 109(8):2087-95. PMC: 3798966. DOI: 10.1038/bjc.2013.570. View

10.

Zhao Z, Zhang Z, Zhang H, Jiang L, Wang M, Sun X . Overexpression of Id-1 protein is a marker in colorectal cancer progression. Oncol Rep. 2008; 19(2):419-24. View

11.

Hu Y, Luo K, Wen J, Zhu Z . Strong expression of Id-1 in metastatic lymph nodes from esophageal squamous cell carcinoma is associated with better clinical outcome. J Thorac Dis. 2018; 10(9):5499-5507. PMC: 6196180. DOI: 10.21037/jtd.2018.09.04. View

12.

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

13.

Chinn S, Myers J . Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. J Clin Oncol. 2015; 33(29):3269-76. PMC: 5320919. DOI: 10.1200/JCO.2015.61.2929. View

14.

Schoppmann S, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R . Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer. 2003; 104(6):677-82. DOI: 10.1002/ijc.11009. View

15.

Benezra R, Davis R, Lockshon D, Turner D, Weintraub H . The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 1990; 61(1):49-59. DOI: 10.1016/0092-8674(90)90214-y. View

16.

Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y . Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer. 2004; 100(6):1110-22. DOI: 10.1002/cncr.20095. View

17.

Kyrgidis A, Tzellos T, Kechagias N, Patrikidou A, Xirou P, Kitikidou K . Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer. 2010; 46(9):1563-72. DOI: 10.1016/j.ejca.2010.02.046. View

18.

Lydiatt W, Patel S, OSullivan B, Brandwein M, Ridge J, Migliacci J . Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(2):122-137. DOI: 10.3322/caac.21389. View

19.

Wu J, Montgomery E . Classification and pathology. Surg Clin North Am. 2008; 88(3):483-520, v-vi. DOI: 10.1016/j.suc.2008.03.007. View

20.

Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y . Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions. BMC Cancer. 2017; 17(1):160. PMC: 5330119. DOI: 10.1186/s12885-017-3154-3. View